Trevena hammered again as the FDA spurns their controversial pain drug — but AcelRx gets a green light
The FDA evidently managed to surprise the die-hard supporters of Trevena today by rejecting their controversial pain drug oliceridine — sending their shares $TRVN down 34 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
